the law firm: "The FDA briefing documents stated that it is "unclear" whether the study results supporting Mesoblast's application are "relevant" to the proposed indication for use. "
what is the logic to go after MSB management and make claim to existing shareholders to pay out for this accusation? Why should not the investigation check FDA staff who involve in preparing the FDA briefing documents?
MSB Trading 2020 - a new dawn, page-771
-
- There are more pages in this discussion • 12,300 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.045(2.98%) |
Mkt cap ! $1.672B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $8.307M | 5.669M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 151320 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 55652 | 2 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |